Clinical characteristics, treatment characteristics, and endpoints assessed in real-world clinical practice of talazoparib in patients with HER2-negative BRCA-associated breast cancer
Summary. Abstract. Talazoparib — poly (adenosine diphosphate-ribose) polymerase inhibitor approved for the treatment of adult patients with BRCA-associated HER2-negative locally advanced or metastatic breast cancer, with approval based on the EMBRACA trial. To date, there are no published data on talazoparib use in the real-world United States (USA). Clinical characteristics, treatment patterns, and clinical outcomes of real-world US patients with BRCA-associated HER2-negative locally advanced or metastatic breast cancer, treated with talazoparib monotherapy were collected via retrospective chart review and summarized using descriptive statistics. Among 84 eligible patients, 35.7% had hormone receptor-positive tumors and 64.3% had triple-negative locally advanced or metastatic breast cancer (TNBC). At talazoparib initiation, 29.8% had an Eastern Cooperative Oncology Group performance status (ECOG PS) ≥2 and 19.0% had brain metastasis. Mutations in BRCA1 or BRCA 2 were detected among 64.3% and 35.7% of patients, respectively. Talazoparib was given as 1st-line therapy in 14.3% of patients, 2nd-line in 40.5%, and 3rd- or 4th-line in 45.2%. Median time to talazoparib treatment failure was 8.5 months (95% CI, 8.0–9.7), median progression-free survival was 8.7 months (95% CI, 8.0–9.9), the median time from initiation to chemotherapy was 12.2 months (95% CI, 10.5–20.1), and the overall response rate was 63.1%. No differences in clinical outcomes were observed between patients with HR-positive/HER2-negative locally advanced or metastatic breast cancer and patients with TNBC by using unadjusted statistical comparisons. Brain metastasis and ECOG PS ≥2 at talazoparib initiation were associated with treatment failure and progression or mortality. Therefore, talazoparib clinical outcomes in this real-world population are consistent with findings from EMBRACA.
To the materials: Savill, K. M. Z., Ivanova, J., Asgarisabet, P., Falkenstein, A., Balanean, A., Niyazov, A., … Mahtani, R. L. (2023). Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer. The Oncologist, XX, 1–11. doi.org/10.1093/oncolo/oyad021.
Leave a comment